Table 2.
Characteristics of patients with evaluable CNS disease.
| N (%) | |
|---|---|
| Number of patients | 15 |
| Median age | 46 (35–69) |
| Patients per site | |
| DFCI | 9 (60) |
| Duke | 5 (33) |
| MDACC | 1 (7) |
| Disease-free interval (years) | |
| DFI <2 | 4 (27) |
| DFI ≥2 | 11 (73) |
| Primary tumor subtypes | |
| HER2+ ER− | 6 (40) |
| HER2+ ER+ | 2 (13) |
| HER2− ER+ | 7 (47) |
| BCBM subtypes | |
| HER2+ ER− | 5 (33) |
| HER2− ER+ | 1 (7) |
| HER2+ ER+ | 8 (53) |
| Unknown | 1 (7) |
| BCBM status per investigator | |
| Untreated | 3 (20) |
| Progressive disease (PD) | 7 (47) |
| Stable disease (SD) | 2 (13) |
| (Neo)adjuvant HER2 therapy | |
| None | 1 (7) |
| Trastuzumab-based | 6 (40) |
| Trastuzumab + lapatinib-based | 1 (7) |
| Trastuzumab + pertuzumab-based | 5 (33) |
| Not available | 2 (13) |
| Metastatic HER2 therapy | |
| Median number of previous HER2 therapies in metastatic setting | 4 (0–10) |
| Trastuzumab | 12 (80) |
| Pertuzumab | 8 (53) |
| Trastuzumab emtansine (T-DM1) | 12 (80) |
| Tyrosine kinase inhibitor | 10 (67) |
| Median interval from last radiation to C1D1 (months) | 13.4 (1.3–18.2) |